(Q54439319)

29 May 2018

title

A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. (English)

1 reference

29 May 2018

1 reference

Tara Baetz

1

1 reference

29 May 2018

Elizabeth Eisenhauer

2

1 reference

29 May 2018

Lillian Siu

3

1 reference

29 May 2018

Martha MacLean

4

1 reference

29 May 2018

Karen Doppler

5

1 reference

29 May 2018

Wendy Walsh

6

1 reference

29 May 2018

Bryn Fisher

7

1 reference

29 May 2018

Azhar Z Khan

8

1 reference

29 May 2018

Dinesh P de Alwis

9

1 reference

29 May 2018

A Weitzman

10

1 reference

29 May 2018

Leslie H Brail

11

1 reference

29 May 2018

Malcolm Moore

12

1 reference

29 May 2018

publication date

5 December 2006

1 reference

29 May 2018

Investigational New Drugs

published in

1 reference

29 May 2018

volume

25

1 reference

29 May 2018

issue

3

1 reference

29 May 2018

page(s)

217-225

1 reference

29 May 2018

https://scigraph.springernature.com/pub.10.1007/s10637-006-9021-8

exact match

0 references

cites work

The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-006-9021-8

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-006-9021-8

Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma

21 January 2018

1 reference

12 December 2020

A novel anti-pancreatic cancer agent, LY293111.

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation

1 reference

12 December 2020

Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111.

1 reference

12 December 2020

Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.

1 reference

12 December 2020

Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors

1 reference

12 December 2020

Phospholipid metabolite expression by head and neck squamous cell carcinoma

1 reference

12 December 2020

VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis

1 reference

12 December 2020

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

1 reference

12 December 2020

1 reference

12 December 2020

Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.

1 reference

12 December 2020

Effect of LY293111 in combination with gemcitabine in colonic cancer

1 reference

12 December 2020

Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis

1 reference

12 December 2020

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

12 December 2020

Lipoxygenase in Human Tumor Cells

1 reference

12 December 2020

Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells

1 reference

12 December 2020

Medical significance of peroxisome proliferator-activated receptors.

1 reference

12 December 2020

Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma and cancers

1 reference

12 December 2020

10.1007/S10637-006-9021-8

Identifiers

DOI

1 reference

29 May 2018

1 reference

29 May 2018